Morandini G, Perduca M, Zannini G, Foschino M P, Miragliotta G, Carnimeo N S
Pneumology Division, Ospedale Maggiore, USSL 25, Verona, Italy.
J Chemother. 1993 Feb;5(1):32-6. doi: 10.1080/1120009x.1993.11739206.
A total of 51 patients with acute exacerbation of chronic bronchitis and pneumonia were enrolled: 27 treated with azithromycin (500 mg once a day for 3 days), and 24 with roxithromycin (150 mg every 12 hours for 7 days). The two regimens were equally effective, with clinical cure in 80% and 72% of patients respectively. Bacteriological eradication on day 19-23 was obtained in 7/11 cases (64%) and in 6/13 cases (46%) in the two groups, respectively. No side effects occurred in patients treated with azithromycin, while they occurred in the roxithromycin group (2 vomiting and 1 gastritis). Clinical and bacteriological efficacy, excellent tolerability, simplified dosage (single daily dose) and short-course (3 days) therapeutic regimen make azithromycin, in our experience, efficacious for the treatment of acute exacerbation of chronic bronchitis and community-acquired pneumonia.
共纳入51例慢性支气管炎急性加重期合并肺炎患者：27例接受阿奇霉素治疗（500mg，每日1次，共3天），24例接受罗红霉素治疗（150mg，每12小时1次，共7天）。两种治疗方案疗效相当，临床治愈率分别为80%和72%。两组在第19 - 23天的细菌清除率分别为7/11例（64%）和6/13例（46%）。接受阿奇霉素治疗的患者未出现副作用，而罗红霉素组出现了副作用（2例呕吐和1例胃炎）。根据我们的经验，临床和细菌学疗效、良好的耐受性、简化的剂量（每日单次剂量）以及短疗程（3天）治疗方案使阿奇霉素对慢性支气管炎急性加重期和社区获得性肺炎的治疗有效。
